Delisting risk
GRI Bio (GRI)
Develops NKT-cell therapies for pulmonary fibrosis and autoimmune disease.
$1.97
Pre-market−0.03 (−1.64%)
At close$2.00(+4.71%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions6 holders · as of Mar 31, 2026 | 1.29% | 28.2K shares | |
| Otherremainder | 98.71% | 2.16M shares |
2.19M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.19M in the company's Sep 3, 2026 report, 89.8K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Institutions13F, as of Mar 31, 2026
6 holders · 28.2K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 18.4K | 0.84% | May 15, 2026 | |
| UBS Group AG | 8.7K | 0.40% | May 5, 2026 | |
| Tower Research Capital LLC (TRC) | 1.1K | 0.05% | May 15, 2026 | |
| BlackRock, Inc. | 7 | 0.00% | May 13, 2026 | |
| Sbi Securities Co., Ltd. | 4 | 0.00% | Apr 28, 2026 | |
| Danske Bank A/S | 2 | 0.00% | May 12, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.